Clinical trial NCT04702997: A Trial of Bardoxolone Methyl in Patients With CKD at Risk of Rapid Progression (MERLIN)
Official title: A Phase 2 Trial to Evaluate Safety, Tolerability, and Efficacy of Bardoxolone Methyl in Patients With Chronic Kidney Disease at Risk of Rapid Progression
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Kidney Diseases
Keywords: Advanced CKD
Chronic Kidney Disease
Bardoxolone methyl
RTA 402
eGFR
Advanced Chronic Kidney Disease
Lead sponsor: Biogen
Sponsor class: INDUSTRY
First posted: 2021-01-11
Enrollment: 81
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This multi-center, randomized, double-blind, placebo-controlled, Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with CKD due to multiple etiologies at risk of rapid disease progression. Approximately 70 patients will be enrolled and randomized 1:1 to either bardoxolone methyl or placebo. Patients with CKD secondary to varying etiologies will be enrolled from age 18-70 years with eGFR ≥ 20 to \< 60 mL/min/1.73 m2, and other risk factors for rapid progression of kidney disease.

The maximum target dose will be determined by baseline proteinuria status. Patients with baseline urine albumin to creatinine ratio (UACR) ≤ 300 mg/g will be titrated to a maximum dose of 20 mg, and patients with baseline UACR \> 300 mg/g will be titrated to a maximum dose of 30 mg. Qualified patients will be randomized 1:1 to receive either bardoxolone methyl or placebo once daily (preferably in the morning) throughout a 12-week dosing period.

Patients in the study will follow the same visit and assessment schedule. Patients will be assessed during treatment at Day 1, Weeks 1, 2, 4, 6, 8, and 12 and by telephone contact on Days 3, 10, 21, 31, 35, and 45. Date of last dose and the end-of-treatment assessments mark the end of the treatment period. Patients will not receive study drug during a 5-week off-treatment period between Weeks 12 and 17. The off-treatment (OT) period includes 5 visits requiring various assessments to characterize eGFR from the time of study drug discontinuation through Day 35 off-treatment.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of CKD with screening eGFR (average of Screen A and Screen B eGFR values) ≥ 20 to \< 60 mL/min/1.73 m2
* Patient must meet at least one of the following criteria:

  1. UACR ≥ 300 mg/g; OR
  2. eGFR decline at a rate of ≥ 4 mL/min/1.73 m2 in prior year; OR
  3. Hematuria defined as \> 5-10 red blood cells (RBCs) per high power field (HPF, manual method), or documented history of positive urinary dipstick for blood in prior year, or macroscopic hematuria in prior 3 years;
* Systolic blood pressure ≤ 150 mmHg and diastolic blood pressure ≤ 90 mmHg at Screen A visit after a period of rest (≥ 5 minutes);
* Treatment with an angiotensin-converting enzyme inhibitor (ACEi) and/or an angiotensin II receptor blocker (ARB) at the maximally tolerated labeled daily dose for at least 6 weeks prior to the Screen A visit and with no anticipated changes to dose(s) during study participation.
* Able to swallow capsules -

Exclusion Criteria:

* Prior exposure to bardoxolone methyl;
* CKD secondary to or associated with any of the following:

  1. History of rapidly progressive glomerulonephritis (RPGN)
  2. Glomerulonephritis requiring immunosuppression in the last 6 months prior to Screen A;
* Concomitant use of tolvaptan.
* Systemic immunosuppression for more than 2 weeks, cumulatively, within the 12 weeks prior to Day 1 or anticipated need for immunosuppression during the study;
* Patients currently taking a sodium/glucose cotransporter-2 inhibitor (SGLT2i), requiring dose adjustments within 12 weeks prior to Day 1 or if dose is anticipated to change during study participation;
* B-type natriuretic peptide (BNP) level \> 200 pg/mL at Screen A visit;
* Uncontrolled diabetes (HbA1c \> 11.0%) at Screen A visit;
* Serum albumin \< 3 g/dL at Screen A visit;
* Kidney or any other solid organ transplant recipient or a planned transplant during the study;
* Acute dialysis or acute kidney injury within 12 weeks prior to Screen A visit or during Screening;
* History of clinically significant cardiac disease;
* Systolic blood pressure \< 90 mmHg at Screen A visit after a period of rest;
* Body mass index \< 18.5 kg/m2 at the Screen A visit;
* History of malignancy within 5 years prior to Screen A visit, with the exception of localized skin or cervical carcinomas;
* Coronavirus disease 2019 (COVID-19) diagnosis within 3 months prior to Screen A or have ever required COVID-19 related hospitalization;
* Participation in other interventional clinical studies within 3 months (or if relevant 5 half-lives of that study medication, whichever is the longer) prior to Screen B;
* Unwilling to practice acceptable methods of birth control;
* Women who are pregnant or breastfeeding.

Primary outcomes:
measure: Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Week 12
timeFrame: Baseline through 12 weeks after participant receives the first dose
Secondary outcomes:
Other outcomes:
Locations:
city: La Mesa
country: United States
facility: California Institute of Renal Research
state: California
city: Arvada
country: United States
facility: Western Nephrology
state: Colorado
city: Denver
country: United States
facility: Colorado Kidney Care
state: Colorado
city: Nampa
country: United States
facility: Boise Kidney & Hypertension, PLLC
state: Idaho
city: Baton Rouge
country: United States
facility: Renal Associates of Baton Rouge
state: Louisiana
city: Kalamazoo
country: United States
facility: Nephrology Center, PC
state: Michigan
city: Las Vegas
country: United States
facility: DaVita Clinical Research
state: Nevada
city: Columbia
country: United States
facility: Columbia Nephrology Associates, PA
state: South Carolina
city: Dallas
country: United States
facility: Renal Disease Research Intitute
state: Texas
city: Houston
country: United States
facility: DaVita Clinical Research
state: Texas
city: McAllen
country: United States
facility: Gamma Medical Research Inc
state: Texas
city: San Antonio
country: United States
facility: Clinical Advancement Center, PLLC
state: Texas
Study officials:
References: